Recombinant human parathyroid hormone (1-34) increases bone mineral density in men with both idiopathic and hypogonadal osteoporosis.

被引：0
|
作者：
Orwoll, ES
Scheele, WH
Clancy, AD
Adami, S
Syversen, U
Kaufman, JM
Diez-Perez, A
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1958
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [1] Brief therapy with recombinant human parathyroid hormone (1-34) increases lumbar spine bone mineral density in men with idiopathic or hypogonadal osteopenia.
    Orwoll, E
    Scheele, WH
    Paul, S
    Adami, S
    Syversen, U
    Diez-Perez, A
    Gaich, GA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S221 - S221
  • [2] Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer, RM
    Arnaud, CD
    Zanchetta, JR
    Prince, R
    Gaich, GA
    Reginster, JY
    Hodsman, AB
    Eriksen, EF
    Ish-Shalom, S
    Genant, HK
    Wang, OH
    Mitlak, BH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (19): : 1434 - 1441
  • [3] Changes in bone mineral density 18 months after cessation of recombinant human parathyroid hormone (1-34) or alendronate treatment in postmenopausal women with osteoporosis.
    Dore, RK
    Hodsman, AB
    Scheele, WH
    Body, JL
    Miller, PD
    Clancy, AD
    Myers, SL
    Gaich, GA
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S254 - S254
  • [4] The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
    Orwoll, E
    Scheele, W
    Paul, S
    Adami, S
    Syversen, U
    Diez-Perez, A
    Kaufman, JM
    Clancy, A
    Gaich, G
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (01) : 9 - 17
  • [5] Lumbar spine bone mineral density response rates in a study of recombinant human parathyroid hormone (1-34) compared to alendronate sodium in postmenopausal women with osteoporosis.
    Kulkarni, PM
    Gaich, GA
    Scheele, WH
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S379 - S379
  • [6] Parathyroid hormone (PTH 1-34) as a treatment for idiopathic osteoporosis in men: Changes in bone mineral density, bone markers, and optimal duration of therapy.
    Kurland, ES
    Cosman, F
    Rosen, CJ
    Lindsay, Z
    Bilezikian, JP
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S230 - S230
  • [7] Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis
    Gillberg, P
    Mallmin, H
    Petrén-Mallmin, M
    Ljunghall, S
    Nilsson, AG
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11): : 4900 - 4906
  • [8] Teriparatide [human parathyroid hormone (1-34)] therapy in men with osteoporosis
    Kaufman, J. -M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S184 - S185
  • [9] Alendronate increases bone mineral density in male idiopathic osteoporosis.
    Weber, TJ
    Drezner, MK
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S278 - S278
  • [10] Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
    Zanchetta, JR
    Bogado, CE
    Ferretti, JL
    Wang, O
    Wilson, MG
    Sato, M
    Gaich, GA
    Dalsky, GP
    Myers, SL
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) : 539 - 543
12345